2020
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent? CardioVascular And Interventional Radiology 2020, 43: 721-731. PMID: 32140840, DOI: 10.1007/s00270-020-02434-4.Peer-Reviewed Original ResearchConceptsC hepatocellular carcinomaChild-Pugh AAdvanced hepatocellular carcinomaOverall survivalHepatocellular carcinomaBCLC stage C hepatocellular carcinomaEastern Cooperative Oncology Group scoreBCLC-C hepatocellular carcinomasMultivariable Cox regression analysisChild-Pugh scoreMedian overall survivalChild-Pugh classKaplan-Meier methodCox regression analysisYttrium-90 RadioembolizationLog-rank testCautious patient selectionSignificant independent predictorsChild-PughHCV infectionResultsMean ageY90 radioembolizationAdditional malignanciesConsecutive patientsIndependent predictors
2010
Adjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2009
Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)
Leichman L, Goldman B, Benedetti J, Billingsley K, Thomas C, Iqbal S, Lenz H, Blanke C, Gold P, Corless C. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). Journal Of Clinical Oncology 2009, 27: 4513-4513. DOI: 10.1200/jco.2009.27.15_suppl.4513.Peer-Reviewed Original ResearchExternal beam radiationPathologic complete responsePhase II trialOverall survivalEsophageal adenocarcinomaII trialSouthwest Oncology Group phase II trialGrade 3/4 toxicitiesMedian overall survivalNon-hematologic toxicitiesCentral pathology reviewPrimary tumor responseCooperative group trialsStandard of careTumor molecular profilesAcceptable toxicityFree survivalModality therapyComplete responseGastric cardiaNew regimensPathology reviewFuture trialsTumor responseSitu cancer